Browsing by Author "Mathew, MS"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
Item Hydrogen-bond assisted, aggregation-induced emission of digitonin(RSC ADVANCES, 2015) Mathew, MS; Sreenivasan, K; Joseph, KContrary to the conventional aggregation-induced emission (AIE) luminogens obtained from the addition of poor solvents to the solution of organic molecules in good solvents, we serendipitously observed the AIE phenomenon arising from the addition of a strong base to the aqueous solution of the aliphatic glycoside molecule digitonin. Detailed spectroscopic and microscopic studies were carried out to unearth the mechanism of this transformation from weakly luminescent form to highly luminescent blue AIEgen. They reveal that the formation of strong inter-and intramolecular hydrogen bonds between the partially deprotonated forms of digitonin, which restricts the molecular rotation, is the main cause of fluorescence enhancement in base-treated digitonin. Quantum yield of the base-treated digitonin is found to be 0.135 with 93% enhancement compared to the parent molecule. Further, photoluminescence intensity of the base-treated digitonin can be tuned by changing the pH from 7-14. We have also shown that the blue-green luminescent base-treated digitonin can effectively transfer excited-state energy to Rhodamine B, which results in white light emission from the digitoninRhodamine mixture.Item Improved Bioavailability of Curcumin in Gliadin-Protected Gold Quantum Cluster for Targeted Delivery(ACS Omega, 2019-09) Mathew, MS; Kavya, V; Jayaram, PS; Jayasree, RS; Kuruvilla, JThis study deals with the synthesis of a gliadin-stabilized gold quantum cluster (AuQC) for the encapsulation of curcumin (CUR) and its targeted delivery to the cancer cell. CUR is an anticancer drug containing a hydrophobic polyphenol derived from the rhizome of Curcuma longa. The utilization of CUR in cancer treatment is limited because of suboptimal pharmacokinetics and poor bioavailability at the tumor site. In order to improve the bioavailability of CUR, we have encapsulated it into AuQCs stabilized by a proline-rich protein gliadin because proline-rich protein has the ability to bind a hydrophobic drug CUR. The encapsulation of CUR into the hydrophobic cavity of the protein was confirmed by various spectroscopic techniques. Compared to CUR alone, the encapsulated CUR was stable against degradation and showed higher pH stability up to pH 8.5. The encapsulation efficiency of CUR in AuQCs was calculated as 98%, which was much higher than the other reported methods. In vitro drug release experiment exhibited a controlled and pH-dependent CUR release over a period of 60 h. The encapsulated CUR-QCs exhibited less toxicity in the normal cell line (L929) and high toxicity in breast cancer (MDA-MB239). Thus, it can be used as a potential material for anticancer therapy and bioimaging.